Immutep Ltd
NASDAQ:IMMP

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
NASDAQ:IMMP
Watchlist
Price: 3.18 USD 8.16% Market Closed
Market Cap: $461.9m

Operating Margin

-116 704%
Current
Declining
by 63 159.7%
vs 3-y average of -53 544.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-116 704%
=
Operating Income
AU$-70.1m
/
Revenue
AU$60.1k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-116 704%
=
Operating Income
$-70.1m
/
Revenue
AU$60.1k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Immutep Ltd
ASX:IMM
671.8m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
167.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 96% of companies in Australia
Percentile
4rd
Based on 3 951 companies
4rd percentile
-116 704%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Immutep Ltd
Glance View

Market Cap
461.9m USD
Industry
Biotechnology

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMMP Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-116 704%
=
Operating Income
AU$-70.1m
/
Revenue
AU$60.1k
What is Immutep Ltd's current Operating Margin?

The current Operating Margin for Immutep Ltd is -116 704%, which is below its 3-year median of -53 544.3%.

How has Operating Margin changed over time?

Over the last 3 years, Immutep Ltd’s Operating Margin has decreased from -15 181.6% to -116 704%. During this period, it reached a low of -116 704% on Jun 30, 2025 and a high of -15 181.6% on Jun 30, 2022.

Back to Top